With an Engineering degree and an MBA, Bernard brings a wealth of expertise to his role as Managing Director of ANS Biotech. Appointed CEO in October 2023, Bernard’s career spans over 25 years of distinguished service in both financial and operational leadership positions within large corporations and family-owned enterprises.
Throughout his career, Bernard has consistently demonstrated exceptional proficiency in financial management, operational efficiency, and strategic planning. His methodical approach and analytical mind have driven financial stability and growth across various organizations, showcasing his ability to navigate complex financial and operational landscapes.
As the CEO of ANS Biotech, Bernard’s expertise and strategic vision are poised to be invaluable assets for the company’s future. His leadership is defined by a commitment to innovation, sustainable growth, and ethical practices, ensuring ANS Biotech’s continued prominence in the biotech industry. Bernard’s dedication to fostering a collaborative and high-performing environment will drive the company’s mission of supporting analgesic drug discovery, steering ANS Biotech towards a prosperous and impactful future.